Zhejiang Garden BiopharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Zhejiang Garden BiopharmaceuticalLtd's earnings have been declining at an average annual rate of -4.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 16% per year. Zhejiang Garden BiopharmaceuticalLtd's return on equity is 7.7%, and it has net margins of 20.9%.
Key information
-4.1%
Earnings growth rate
-7.4%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 16.0% |
Return on equity | 7.7% |
Net Margin | 20.9% |
Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Zhejiang Garden BiopharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1,108 | 232 | 349 | 95 |
31 Dec 23 | 1,095 | 192 | 376 | 91 |
30 Sep 23 | 1,237 | 179 | 437 | 87 |
30 Jun 23 | 1,274 | 204 | 466 | 83 |
31 Mar 23 | 1,348 | 284 | 466 | 70 |
01 Jan 23 | 1,418 | 384 | 447 | 70 |
30 Sep 22 | 1,427 | 466 | 428 | 66 |
30 Jun 22 | 1,385 | 461 | 414 | 63 |
31 Mar 22 | 1,329 | 543 | 338 | 69 |
01 Jan 22 | 1,117 | 484 | 258 | 59 |
30 Sep 21 | 937 | 409 | 192 | 58 |
30 Jun 21 | 847 | 420 | 117 | 53 |
31 Mar 21 | 699 | 293 | 97 | 44 |
31 Dec 20 | 659 | 263 | 93 | 45 |
30 Sep 20 | 630 | 261 | 71 | 35 |
30 Jun 20 | 645 | 277 | 71 | 38 |
31 Mar 20 | 617 | 276 | 70 | 42 |
31 Dec 19 | 718 | 344 | 68 | 43 |
30 Sep 19 | 763 | 392 | 71 | 47 |
30 Jun 19 | 758 | 384 | 76 | 44 |
31 Mar 19 | 661 | 315 | 74 | 36 |
01 Jan 19 | 660 | 307 | 68 | 31 |
30 Sep 18 | 585 | 252 | 57 | 32 |
30 Jun 18 | 508 | 208 | 47 | 31 |
31 Mar 18 | 569 | 232 | 49 | 25 |
01 Jan 18 | 420 | 130 | 53 | 22 |
30 Sep 17 | 416 | 120 | 62 | 6 |
30 Jun 17 | 403 | 103 | 62 | 0 |
31 Mar 17 | 355 | 60 | 72 | 0 |
31 Dec 16 | 329 | 44 | 68 | 0 |
30 Sep 16 | 272 | 29 | 58 | 0 |
30 Jun 16 | 239 | 17 | 62 | 0 |
31 Mar 16 | 178 | 10 | 47 | 0 |
31 Dec 15 | 151 | 12 | 48 | 0 |
30 Sep 15 | 152 | 22 | 51 | 0 |
30 Jun 15 | 158 | 33 | 47 | 0 |
31 Mar 15 | 163 | 38 | 50 | 0 |
31 Dec 14 | 159 | 37 | 49 | 0 |
30 Sep 14 | 158 | 40 | 49 | 0 |
31 Dec 13 | 184 | 36 | 45 | 0 |
Quality Earnings: 300401 has a large one-off gain of CN¥89.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300401's current net profit margins (20.9%) are lower than last year (21.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300401's earnings have declined by 4.1% per year over the past 5 years.
Accelerating Growth: 300401's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300401 had negative earnings growth (-18.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.01%).
Return on Equity
High ROE: 300401's Return on Equity (7.7%) is considered low.